Obstetrics, Gynecology and Reproduction

Advanced search


Full Text:


The aim of the study was to search for a connection between the abnormal location of placenta and the presence of genetic and acquired forms of thrombophilia.

Materials and methods. A total of 132 women with the aggravated obstetrical history were examined: Group 1 – 42 patients with the history of placenta previa; Group 2 – 60 pregnant women diagnosed with placenta previa in the current pregnancy; Group 3 – 30 pregnant women with the history of placenta previa and the same abnormality in the current pregnancy. The control group included 120 women with no abnormalities in their obstetric history and with normal location of placenta during the current pregnancy. All patients were assessed for the antiphospholipid antibodies using an enzyme immunoassay. The presence of genetic forms of thrombophilia was tested (with polymerase chain reaction and three pairs of oligonucleotide primers) for the following mutations: the C677T mutation in the 5,10-methylenetetrafolate reductase gene, the prothrombin mutation in the G20210A gene, mutations in the Leiden factor V gene, polymorphism 675 4G/5G in the gene of the inhibitor of plasminogen activator type 1, polymorphism 455G/A in the fibrinogen gene.

Results. The thrombophilia spectrum in patients with placenta previa during the current pregnancy and those with abnormal placenta location in the past did not significantly differ from each other. However, in patients with both abnormal placental locations in the past and the present pregnancy, there was a greater occurrence of both genetic and acquired forms of thrombophilia. In the control group, much fewer cases of either genetic or acquired thrombophilia were found.

Conclusion. The obtained results suggest a connection between thrombophilia and the abnormal location of placenta. Women with the abnormal placenta location either in the past or during the current pregnancy should be routinely tested for the genetic markers of thrombophilia and for hemostasis abnormalities.

About the Author

V. B. Zubenko
Stavropol Regional Clinical Perinatal Center № 1
Russian Federation

Zubenko Vladislav Borisovich – Head of Department of Obstetrics.

3/1, ul. Semashko, Stavropol, 355029


1. Medyannikova I.V. Features of the course of pregnancy and childbirth for abnormalities of placentation [Osobennosti techeniya beremennosti i rodov pri anomaliyah placentacii]. Vestnik Kuzbasskogo nauchnogo centra. 2007; 4: 86-7 (in Russian).

2. Coulam C.B., Jeyendran R.S., Fishel L.A., Roussev R. Multiple thrombophilic gene mutations are risk factors for implantation failure. Reprod Biomed Online. 2006; 12 (3): 322 7.

3. Medyannikova I.V. Obstetrical and perinatal aspects of abnormal placentation [Akusherskie i perinatal'nye aspekty anomal'noj placentacii]. Avtoref. dis. kand. med. nauk. Perm'. 2007: 23 s (in Russian).

4. Bitsadze V.O. Pathogenesis, principles of diagnosis and prevention of complications of pregnancy, caused by thrombophilia [Patogenez, principy diagnostiki i profilaktiki oslozhnenij beremennosti, obuslovlennyh trombofiliej]. Avtoref. dis. dokt. med. nauk. Moskva. 2004: 46 s (in Russian).

5. Makatsariya A.D., Bitsadze V.O. Thrombophilia and antithrombotic therapy in obstetric practice [Trombofilii i protivotromboticheskaya terapiya v akusherskoj praktike]. Moskva: Triada-X. 2003: 904 s (in Russian).

6. Makatsariya A.D., Bitsadze V.O., Akinshina S.V. Thrombosis and thromboembolism in the obstetric- gynecological clinic: molecular genetic mechanisms and strategy for the prevention of thromboembolic complications: a guideline for physicians [Trombozy i tromboembolii v akushersko-ginekologicheskoj klinike: molekulyarno-geneticheskie mekhanizmy i strategiya profilaktiki tromboembolicheskih oslozhnenij: rukovodstvo dlya vrachej]. Moskva: MIA. 2007: 1064 s (in Russian).

7. Qublan H., Amarin Z., Dabbas M. et al. Low-molecular-weight heparin in the treatment of recurrent IVF-ET failure and thrombophilia: a prospective randomized placebo-controlled trial. Hum Fertil (Camb). 2008; 11: 246-53.

8. Achache H., Revel A. Endometrial receptivity markers, the journey to successful embryo implantation. Hum Reprod Updatе. 2006; 12 (6): 731-46.

9. Azem F., Many A., Ben Ami I. et al. Increased rates of thrombophilia in women with repeated IVF failures. Hum Reprod. 2004; 19: 368-70.

10. Berker B., Taskin S., Kahraman K., Taskin E.A., Atabekoglu C., Sonmezer M. The role of low-molecular-weight heparin in recurrent implantation failure: a prospective, quasirandomized, controlled study. Fertil Steril. 2011; 95 (8): 2499-502.

11. Assou S., Boumela I., Haouzi D. et al. Dynamic changes in gene expression during human early embryo development: from fundamental aspects to clinical applications. Hum Reprod Updatе. 2011; 17 (2): 272-90.

12. Baymuradova S.M. Pathogenesis, principles of diagnosis, prevention and therapy of fetal loss syndrome caused by acquired and genetic defects of hemostasis [Patogenez, principy diagnostiki, profilaktiki i terapii sindroma poteri ploda, obuslovlennogo priobretennymi i geneticheskimi defektami gemostaza]. Avtoref. dis. dokt. med. nauk. Moskva. 2007: 46 s (in Russian).

13. Redline R.W. Thrombophilia and placental pathology. Clin Obstet Gynecol. 2006; 49 (4): 885-94.

14. Gogia N., Machin G.A. Maternal thrombophilias are associated with specific placental lesions. Pediatr Dev Pathol. 2008; 11 (6): 424-9.


For citations:

Zubenko V.B. THROMBOPHILIA AND ABNORMAL LOCATION OF PLACENTA. Obstetrics, Gynecology and Reproduction. 2018;12(1):17-22. (In Russ.)

Views: 580

ISSN 2313-7347 (Print)
ISSN 2500-3194 (Online)